Pulmonary Airway Narrowing

Pulmonary airway narrowing refers to the reduction in airway diameter, which impedes airflow and increases resistance within the bronchial tree. This condition is commonly associated with diseases such as asthma, chronic obstructive pulmonary disease, bronchiectasis, and bronchiolitis, where inflammation, mucus accumulation, or structural remodeling contributes to obstruction. Clinically, patients may experience wheezing, coughing, chest tightness, and difficulty breathing, particularly during physical exertion or acute flare-ups. Recurrent or severe narrowing can lead to ventilation-perfusion mismatch, impaired gas exchange, and increased susceptibility to respiratory infections. Diagnosis relies on a combination of clinical evaluation, imaging, and functional testing. Spirometry is the cornerstone for quantifying airflow limitation, highlighting parameters such as forced expiratory volume in one second (FEV1) and FEV1/FVC ratio. High-resolution computed tomography can reveal structural changes such as airway wall thickening, luminal narrowing, and mucus plugging, while bronchoscopy may provide direct visualization and enable therapeutic interventions. Management strategies target both the underlying cause and symptomatic relief. Pharmacologic therapy includes bronchodilators, corticosteroids, and biologics tailored to the specific disease mechanism. Pulmonary rehabilitation, airway clearance techniques, and patient education on inhaler use further enhance treatment efficacy. In selected cases, interventional procedures like bronchial thermoplasty or stent placement may be employed to mechanically improve airway caliber. By combining precise diagnostics, individualized therapy, and supportive measures, management of pulmonary airway narrowing aims to reduce symptom burden, improve airflow, and enhance daily functional capacity.